FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> layoffs | GlaxoSmithKline

Ailing GlaxSmithKline to axe 350 R&D workers

Tools

In an effort to shake up an organization that has produced few major advances recently, GlaxoSmithKline announced plans to axe 350 jobs in its R&D operations. The cuts--part of a major restructuring announced last fall--will terminate staffers at three labs in the U.S., Italy and Germany. These layoffs reflect the CEO Andrew Witty's strategic move to look outside the company for innovations in drug technology. Report

More stories about layoffs   GlaxoSmithKline  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.